MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale of
common stock, net of...
$20,348,653
Proceeds from the
exercise of stock options
$38,274
Net cash provided by
financing activities
$20,386,927
Net increase in cash
and cash...
$8,483,024
Canceled cashflow
$11,903,903
Stock-based compensation,
including the issuance of...
$4,290,315
Prepaids and other
current assets
-$2,852,434
Acquired in-process
research and development
$2,289,602
Accrued expenses
$1,099,853
Deferred collaboration
revenue
$454,247
Depreciation
$27,361
Net cash used in
operating activities
-$10,739,301
Net cash used in
investing activities
-$1,164,602
Canceled cashflow
$11,013,812
Net loss
-$21,226,107
Purchase of in-process
research and development...
$1,164,602
Accounts payable
-$527,006
Collaboration revenue
$7,945,753
Other income
$1,332,207
Pre-tax loss
-$21,223,018
Income tax benefit
$3,089
Canceled cashflow
$9,277,960
Total research and
development expenses
$16,734,549
Total general and
administrative expenses
$11,449,466
In-process research and
development
$2,289,602
Depreciation
$27,361
Back
Back
Cash Flow
source: myfinsight.com
Coya Therapeutics, Inc. (COYA)
Coya Therapeutics, Inc. (COYA)